-
1
-
-
11144358403
-
Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study
-
Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ. 2004. Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology 126:1302-1311.
-
(2004)
Gastroenterology
, vol.126
, pp. 1302-1311
-
-
Afdhal, N.H.1
Dieterich, D.T.2
Pockros, P.J.3
Schiff, E.R.4
Shiffman, M.L.5
Sulkowski, M.S.6
Wright, T.7
Younossi, Z.8
Goon, B.L.9
Tang, K.L.10
Bowers, P.J.11
-
2
-
-
84855833690
-
Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: A systematic review and meta-analysis
-
Alavian SM, Tabatabaei SV, Behnava B. 2012. Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: A systematic review and meta-analysis. J Viral Hepat 19:88-93.
-
(2012)
J Viral Hepat
, vol.19
, pp. 88-93
-
-
Alavian, S.M.1
Tabatabaei, S.V.2
Behnava, B.3
-
3
-
-
0033646209
-
Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. The liver cancer study group of Japan
-
Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K, Yamada R. 2000. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. The liver cancer study group of Japan. Hepatology 32:1224-1229.
-
(2000)
Hepatology
, vol.32
, pp. 1224-1229
-
-
Arii, S.1
Yamaoka, Y.2
Futagawa, S.3
Inoue, K.4
Kobayashi, K.5
Kojiro, M.6
Makuuchi, M.7
Nakamura, Y.8
Okita, K.9
Yamada, R.10
-
4
-
-
13944250319
-
Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin
-
Balan V, Schwartz D, Wu GY, Muir AJ, Ghalib R, Jackson J, Keeffe EB, Rossaro L, Burnett A, Goon BL, Bowers PJ, Leitz GJ. 2005. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. Am J Gastroenterol 100:299-307.
-
(2005)
Am J Gastroenterol
, vol.100
, pp. 299-307
-
-
Balan, V.1
Schwartz, D.2
Wu, G.Y.3
Muir, A.J.4
Ghalib, R.5
Jackson, J.6
Keeffe, E.B.7
Rossaro, L.8
Burnett, A.9
Goon, B.L.10
Bowers, P.J.11
Leitz, G.J.12
-
5
-
-
10744232465
-
Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data
-
Camma C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, Marcellin P, Balart L, Alberti A, Craxi A. 2004. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data. Hepatology 39:333-342.
-
(2004)
Hepatology
, vol.39
, pp. 333-342
-
-
Camma, C.1
Di Bona, D.2
Schepis, F.3
Heathcote, E.J.4
Zeuzem, S.5
Pockros, P.J.6
Marcellin, P.7
Balart, L.8
Alberti, A.9
Craxi, A.10
-
6
-
-
0031041924
-
Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
-
Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G. 1997. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 112:463-472.
-
(1997)
Gastroenterology
, vol.112
, pp. 463-472
-
-
Fattovich, G.1
Giustina, G.2
Degos, F.3
Tremolada, F.4
Diodati, G.5
Almasio, P.6
Nevens, F.7
Solinas, A.8
Mura, D.9
Brouwer, J.T.10
Thomas, H.11
Njapoum, C.12
Casarin, C.13
Bonetti, P.14
Fuschi, P.15
Basho, J.16
Tocco, A.17
Bhalla, A.18
Galassini, R.19
Noventa, F.20
Schalm, S.W.21
Realdi, G.22
more..
-
7
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
-
(2002)
N Engl J Med
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
Smith, C.4
Marinos, G.5
Goncales, F.L.6
Haussinger, D.7
Diago, M.8
Carosi, G.9
Dhumeaux, D.10
Craxi, A.11
Lin, A.12
Hoffman, J.13
Yu, J.14
-
8
-
-
80051767247
-
Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma
-
Hagihara H, Nouso K, Kobayashi Y, Iwasaki Y, Nakamura S, Kuwaki K, Toshimori J, Miyatake H, Ohnishi H, Shiraha H, Yamamoto K. 2011. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Clin Oncol 16:210-220.
-
(2011)
Int J Clin Oncol
, vol.16
, pp. 210-220
-
-
Hagihara, H.1
Nouso, K.2
Kobayashi, Y.3
Iwasaki, Y.4
Nakamura, S.5
Kuwaki, K.6
Toshimori, J.7
Miyatake, H.8
Ohnishi, H.9
Shiraha, H.10
Yamamoto, K.11
-
9
-
-
65449171953
-
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
-
Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourliere M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360:1839-1850.
-
(2009)
N Engl J Med
, vol.360
, pp. 1839-1850
-
-
Hezode, C.1
Forestier, N.2
Dusheiko, G.3
Ferenci, P.4
Pol, S.5
Goeser, T.6
Bronowicki, J.P.7
Bourliere, M.8
Gharakhanian, S.9
Bengtsson, L.10
McNair, L.11
George, S.12
Kieffer, T.13
Kwong, A.14
Kauffman, R.S.15
Alam, J.16
Pawlotsky, J.M.17
Zeuzem, S.18
-
10
-
-
57349090407
-
Gene expression in fixed tissues and outcome in hepatocellular carcinoma
-
Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. 2008. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359:1995-2004.
-
(2008)
N Engl J Med
, vol.359
, pp. 1995-2004
-
-
Hoshida, Y.1
Villanueva, A.2
Kobayashi, M.3
Peix, J.4
Chiang, D.Y.5
Camargo, A.6
Gupta, S.7
Moore, J.8
Wrobel, M.J.9
Lerner, J.10
Reich, M.11
Chan, J.A.12
Glickman, J.N.13
Ikeda, K.14
Hashimoto, M.15
Watanabe, G.16
Daidone, M.G.17
Roayaie, S.18
Schwartz, M.19
Thung, S.20
Salvesen, H.B.21
Gabriel, S.22
Mazzaferro, V.23
Bruix, J.24
Friedman, S.L.25
Kumada, H.26
Llovet, J.M.27
Golub, T.R.28
more..
-
11
-
-
84879604456
-
Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma
-
Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY. 2013. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology 58:150-157.
-
(2013)
Hepatology
, vol.58
, pp. 150-157
-
-
Hsu, Y.C.1
Ho, H.J.2
Wu, M.S.3
Lin, J.T.4
Wu, C.Y.5
-
12
-
-
0032955838
-
The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States
-
Hu KQ, Tong MJ. 1999. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 29: 1311-1316.
-
(1999)
Hepatology
, vol.29
, pp. 1311-1316
-
-
Hu, K.Q.1
Tong, M.J.2
-
13
-
-
0033854015
-
Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer
-
Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. 2000. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32:228-232.
-
(2000)
Hepatology
, vol.32
, pp. 228-232
-
-
Ikeda, K.1
Arase, Y.2
Saitoh, S.3
Kobayashi, M.4
Suzuki, Y.5
Suzuki, F.6
Tsubota, A.7
Chayama, K.8
Murashima, N.9
Kumada, H.10
-
14
-
-
0345600107
-
Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients
-
Ikeda K, Kobayashi M, Saitoh S, Someya T, Hosaka T, Akuta N, Suzuki F, Tsubota A, Suzuki Y, Arase Y, Kumada H. 2003. Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients. Oncology 65:204-210.
-
(2003)
Oncology
, vol.65
, pp. 204-210
-
-
Ikeda, K.1
Kobayashi, M.2
Saitoh, S.3
Someya, T.4
Hosaka, T.5
Akuta, N.6
Suzuki, F.7
Tsubota, A.8
Suzuki, Y.9
Arase, Y.10
Kumada, H.11
-
15
-
-
0034525250
-
Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma
-
Kubo S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Ikebe T, Yamamoto T, Wakasa K, Nishiguchi S, Kuroki T, Kinoshita H. 2000. Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. World J Surg 24:1559-1565.
-
(2000)
World J Surg
, vol.24
, pp. 1559-1565
-
-
Kubo, S.1
Hirohashi, K.2
Tanaka, H.3
Tsukamoto, T.4
Shuto, T.5
Ikebe, T.6
Yamamoto, T.7
Wakasa, K.8
Nishiguchi, S.9
Kuroki, T.10
Kinoshita, H.11
-
16
-
-
0032991499
-
Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma
-
Kubo S, Nishiguchi S, Shuto T, Tanaka H, Tsukamoto T, Hirohashi K, Ikebe T, Wakasa K, Kuroki T, Kinoshita H. 1999. Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma. Jpn J Cancer Res 90:162-170.
-
(1999)
Jpn J Cancer Res
, vol.90
, pp. 162-170
-
-
Kubo, S.1
Nishiguchi, S.2
Shuto, T.3
Tanaka, H.4
Tsukamoto, T.5
Hirohashi, K.6
Ikebe, T.7
Wakasa, K.8
Kuroki, T.9
Kinoshita, H.10
-
17
-
-
84901595218
-
Paclatasvir plus asunaprevir for chronic HCV genotype 1b infection
-
Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. 2014. Paclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59:2083-2091.
-
(2014)
Hepatology
, vol.59
, pp. 2083-2091
-
-
Kumada, H.1
Suzuki, Y.2
Ikeda, K.3
Toyota, J.4
Karino, Y.5
Chayama, K.6
Kawakami, Y.7
Ido, A.8
Yamamoto, K.9
Takaguchi, K.10
Izumi, N.11
Koike, K.12
Takehara, T.13
Kawada, N.14
Sata, M.15
Miyagoshi, H.16
Eley, T.17
McPhee, F.18
Damokosh, A.19
Ishikawa, H.20
Hughes, E.21
more..
-
18
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958-965.
-
(2001)
Lancet
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
Rustgi, V.K.4
Shiffman, M.5
Reindollar, R.6
Goodman, Z.D.7
Koury, K.8
Ling, M.9
Albrecht, J.K.10
-
19
-
-
0345299824
-
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis
-
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. 1996. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693-699.
-
(1996)
N Engl J Med
, vol.334
, pp. 693-699
-
-
Mazzaferro, V.1
Regalia, E.2
Doci, R.3
Andreola, S.4
Pulvirenti, A.5
Bozzetti, F.6
Montalto, F.7
Ammatuna, M.8
Morabito, A.9
Gennari, L.10
-
20
-
-
36549047972
-
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C
-
McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH. 2007. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 357:2227-2236.
-
(2007)
N Engl J Med
, vol.357
, pp. 2227-2236
-
-
McHutchison, J.G.1
Dusheiko, G.2
Shiffman, M.L.3
Rodriguez-Torres, M.4
Sigal, S.5
Bourliere, M.6
Berg, T.7
Gordon, S.C.8
Campbell, F.M.9
Theodore, D.10
Blackman, N.11
Jenkins, J.12
Afdhal, N.H.13
-
21
-
-
65449152185
-
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
-
McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ. 2009. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360:1827-1838.
-
(2009)
N Engl J Med
, vol.360
, pp. 1827-1838
-
-
McHutchison, J.G.1
Everson, G.T.2
Gordon, S.C.3
Jacobson, I.M.4
Sulkowski, M.5
Kauffman, R.6
McNair, L.7
Alam, J.8
Muir, A.J.9
-
22
-
-
77950817619
-
Telaprevir for previously treated chronic HCV infection
-
McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM. 2010. Telaprevir for previously treated chronic HCV infection. N Engl J Med 362:1292-1303.
-
(2010)
N Engl J Med
, vol.362
, pp. 1292-1303
-
-
McHutchison, J.G.1
Manns, M.P.2
Muir, A.J.3
Terrault, N.A.4
Jacobson, I.M.5
Afdhal, N.H.6
Heathcote, E.J.7
Zeuzem, S.8
Reesink, H.W.9
Garg, J.10
Bsharat, M.11
George, S.12
Kauffman, R.S.13
Adda, N.14
Di Bisceglie, A.M.15
-
23
-
-
77950220516
-
Meta-analysis: Interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma
-
Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. 2010. Meta-analysis: Interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 17:287-292.
-
(2010)
J Viral Hepat
, vol.17
, pp. 287-292
-
-
Miyake, Y.1
Takaki, A.2
Iwasaki, Y.3
Yamamoto, K.4
-
24
-
-
84902550644
-
Post-treatment levels of alpha-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy
-
Oze T, Hiramatsu N, Yakushijin T, Miyazaki M, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hamasaki T, Hayashi N, Takehara T. 2014. Post-treatment levels of alpha-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol 12:1186-1195.
-
(2014)
Clin Gastroenterol Hepatol
, vol.12
, pp. 1186-1195
-
-
Oze, T.1
Hiramatsu, N.2
Yakushijin, T.3
Miyazaki, M.4
Yamada, A.5
Oshita, M.6
Hagiwara, H.7
Mita, E.8
Ito, T.9
Fukui, H.10
Inui, Y.11
Hijioka, T.12
Inada, M.13
Katayama, K.14
Tamura, S.15
Yoshihara, H.16
Inoue, A.17
Imai, Y.18
Hayashi, E.19
Kato, M.20
Miyagi, T.21
Yoshida, Y.22
Tatsumi, T.23
Kasahara, A.24
Hamasaki, T.25
Hayashi, N.26
Takehara, T.27
more..
-
25
-
-
0030933395
-
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups
-
Poynard T, Bedossa P, Opolon P. 1997. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349:825-832.
-
(1997)
Lancet
, vol.349
, pp. 825-832
-
-
Poynard, T.1
Bedossa, P.2
Opolon, P.3
-
26
-
-
0036242165
-
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
-
Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. 2002. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122:1303-1313.
-
(2002)
Gastroenterology
, vol.122
, pp. 1303-1313
-
-
Poynard, T.1
McHutchison, J.2
Manns, M.3
Trepo, C.4
Lindsay, K.5
Goodman, Z.6
Ling, M.H.7
Albrecht, J.8
-
27
-
-
0031960043
-
Determinants of outcome of compensated hepatitis C virus-related cirrhosis
-
Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R. 1998. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 27:1435-1440.
-
(1998)
Hepatology
, vol.27
, pp. 1435-1440
-
-
Serfaty, L.1
Aumaitre, H.2
Chazouilleres, O.3
Bonnand, A.M.4
Rosmorduc, O.5
Poupon, R.E.6
Poupon, R.7
-
28
-
-
77952422635
-
Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach
-
Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. 2010. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach. J Hepatol 52:889-894.
-
(2010)
J Hepatol
, vol.52
, pp. 889-894
-
-
Shen, Y.C.1
Hsu, C.2
Chen, L.T.3
Cheng, C.C.4
Hu, F.C.5
Cheng, A.L.6
-
29
-
-
84872016931
-
Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips
-
Shen J, Wang S, Zhang YJ, Wu HC, Kibriya MG, Jasmine F, Ahsan H, Wu DP, Siegel AB, Remotti H, Santella RM. 2013. Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips. Epigenetics 8:34-43.
-
(2013)
Epigenetics
, vol.8
, pp. 34-43
-
-
Shen, J.1
Wang, S.2
Zhang, Y.J.3
Wu, H.C.4
Kibriya, M.G.5
Jasmine, F.6
Ahsan, H.7
Wu, D.P.8
Siegel, A.B.9
Remotti, H.10
Santella, R.M.11
-
30
-
-
84856676800
-
Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection
-
Tanimoto Y, Tashiro H, Aikata H, Amano H, Oshita A, Kobayashi T, Kuroda S, Tazawa H, Takahashi S, Itamoto T, Chayama K, Ohdan H. 2012. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection. Ann Surg Oncol 19:418-425.
-
(2012)
Ann Surg Oncol
, vol.19
, pp. 418-425
-
-
Tanimoto, Y.1
Tashiro, H.2
Aikata, H.3
Amano, H.4
Oshita, A.5
Kobayashi, T.6
Kuroda, S.7
Tazawa, H.8
Takahashi, S.9
Itamoto, T.10
Chayama, K.11
Ohdan, H.12
-
31
-
-
20044386501
-
Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases
-
Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, Fujishima T, Yoshida H, Kawabe T, Omata M. 2005. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 103:1201-1209.
-
(2005)
Cancer
, vol.103
, pp. 1201-1209
-
-
Tateishi, R.1
Shiina, S.2
Teratani, T.3
Obi, S.4
Sato, S.5
Koike, Y.6
Fujishima, T.7
Yoshida, H.8
Kawabe, T.9
Omata, M.10
-
32
-
-
53549084881
-
Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma
-
Uenishi T, Nishiguchi S, Tanaka S, Yamamoto T, Takemura S, Kubo S. 2008. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol 98:358-362.
-
(2008)
J Surg Oncol
, vol.98
, pp. 358-362
-
-
Uenishi, T.1
Nishiguchi, S.2
Tanaka, S.3
Yamamoto, T.4
Takemura, S.5
Kubo, S.6
|